National Cancer Institute of Thailand Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2017
NCT01741038
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

National Cancer Institute of Thailand | National Cancer Institute, Thailand

Active Ingredients

Drugs in Phase 3 Trials (1)

allostim (1 trial)

Drugs in Other Trials (1)

coronavac (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2